Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
CARLSBAD, Calif., Feb. 2, 2024 /PRNewswire/ — Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the PIPE) for gross proceeds of approximately $200 million.
Related news for (TYRA)
- Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia
- Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights
- Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
- Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights
- Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights